Reply to T.J. Powles et al

Affiliations

¹ Sukhbinder Dhesy-Thind, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; Glenn G. Fletcher, McMaster University, Hamilton, Ontario, Canada; Mark Clemons, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; and Catherine Van Poznak, University of Michigan, Ann Arbor, MI.

Comment

Sukhbinder Dhesy-Thind et al. J Clin Oncol. 2017.

. 2017 Aug 10;35(23):2720-2721.

doi: 10.1200/JCO.2017.73.8567. Epub 2017 Jun 27.

¹ Sukhbinder Dhesy-Thind, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; Glenn G. Fletcher, McMaster University, Hamilton, Ontario, Canada; Mark Clemons, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; and Catherine Van Poznak, University of Michigan, Ann Arbor, MI.

No abstract available

Comment on

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH. Dhesy-Thind S, et al. J Clin Oncol. 2017 Jun 20;35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257. Epub 2017 Mar 6. J Clin Oncol. 2017. PMID: 28618241
Optimal Use of Adjuvant Bisphosphonates and Breast Cancer.
Powles TJ, Paterson AHG, Gralow JR. Powles TJ, et al. J Clin Oncol. 2017 Aug 10;35(23):2719-2720. doi: 10.1200/JCO.2017.73.6157. Epub 2017 Jun 27. J Clin Oncol. 2017. PMID: 28654362 No abstract available.